ExpreS2ion Biotechnologies partner Bavarian today announced an updated design and trial design for the Phase 3 covid-19 candidate. The Phase 3 is now expected to start August 2022, againt the earlier timeline stated H1 2022; however, crucially the data read-out will stay before year end 22. On the positive side, the trial now will include a licensed mRNA vaccine named Comirnaty® (Pfizer/Biontech) as a comparator, thereby showing non-inferiority to a licensed vaccine. This will give more robust data and a better chance to show advantages to current vaccines (standard treatment). The share is down 3% today, less than the general biotech sector, so the market might weigh the advantage on the study’s design higher than the small delay.

HC Andersen Capital modtager betaling fra ExpreS2ion Biotechnologies for en #DigitalIR aftale.